Enterics for Global Health (EFGH)

Sponsor

University of Washington (Other)

Overall Status

Recruiting

CT.gov ID

NCT06047821

Collaborator

Aga Khan University (Other), International Centre for Diarrhoeal Disease Research, Bangladesh (Other), University of Maryland, Baltimore (Other), University of Virginia (Other), Asociacion Benefica Prisma (Other), Medical Research Council Unit, The Gambia (Other), Kenya Medical Research Institute (Other), Center for Vaccine Development - Mali (Other), Malawi-Liverpool-Wellcome Trust Clinical Research Programme (Other), Bill and Melinda Gates Foundation (Other)

9,800

Enrollment

Locations

33.2

Anticipated Duration (Months)

297

Patients Per Site

8.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Diarrhea remains a leading cause of death among young children, with the majority of diarrhea deaths occurring in low- and middle-income countries. Childhood diarrhea caused by a type of bacteria called "Shigella" is responsible for an estimated 60,000 deaths each year and may cause particularly severe illness among children. Currently, there are several promising vaccines to prevent Shigella diarrhea in development, but key information is still needed to inform future vaccine studies. The purpose of this study, titled Enterics for Global Health (or the "EFGH"), is to determine the number and rate of new cases of Shigella diarrhea among children 6 to 35 months of age presenting to health facilities with diarrhea or dysentery. Over a two-year period, the EFGH study will enroll 1,400 children from each of the seven countries: Peru, Pakistan, Bangladesh, Mali, Malawi, Kenya, and The Gambia (9,800 children total).

Condition or Disease	Intervention/Treatment	Phase
Shigella Child Diarrhea

Detailed Description

In low- and middle-income countries, nearly one third of children experience at least one episode of Shigella-attributable diarrhea during their first 2 years of life. In addition to it being a leading cause of diarrhea, this enteric bacterium is also associated with linear growth faltering, a precursor to stunting. Stunting is a marker of vulnerability to childhood infection, decreased vaccine efficacy and lifelong morbidity. Currently, several promising Shigella vaccines are in development. Eventual Phase 2b/3 Shigella vaccine trials will require a consortium of potential vaccine trial sites in settings with a high incidence of Shigella-attributed medically-attended diarrhea, high participant retention, and the laboratory capacity to confirm Shigella infection. The Enterics for Global Health (EFGH) Shigella burden study will employ cross-sectional and longitudinal study designs to establish updated incidence rates and document consequences of Shigella diarrhea within 7 country sites in Africa, Asia, and Latin America. Over a two-year period, the EFGH study will enroll 9,800 children (1,400 per country site) between 6-35 months with medically-attended diarrhea. Through this multi-country surveillance network, selected EFGH sites will be ready to quickly implement rigorous and efficient vaccine trials and provide critical data to policy makers about the relative importance of this vaccine-preventable disease, accelerating the time to vaccine availability and uptake among children in high Shigella burden settings.

Primary Aims

Determine the incidence of Shigella-attributed medically-attended diarrhea in children 6 to 35 months of age in each of the EFGH country sites.

Secondary Aims

Determine the incidence of Shigella medically-attended diarrhea by serotype, severity definition, laboratory method (culture vs. qPCR), age, and by season.
Describe the prevalence of resistance to commonly used antibiotics in Shigella isolates in each EFGH country site.
Determine the risk of death, hospitalization, persistent diarrhea, diarrhea recurrence, and linear growth faltering in the 3 months following an episode of Shigella medically-attended diarrhea.
Compare various severity definitions in their ability to distinguish Shigella from non-Shigella attributable diarrhea and ability to predict risk of death or hospitalization in the subsequent 3 months.
Quantify the cost incurred by families and health care systems due to Shigella morbidity and mortality.
Identify optimal laboratory methods for Shigella culture by:
comparing the isolation rate of Shigella between two transport media for rectal swabs (Cary-Blair and modified Buffered Glycerol Saline [BGS])
comparing the isolation rate of Shigella between two fecal sample types (rectal swabs and whole stool) among the subset of children who produced whole stool in The Gambia and Bangladesh country sites.

Study Design

Study Type:

Observational

Anticipated Enrollment :

9800 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

The Incidence and Burden of Shigella Diarrhea in Children Aged 6-35 Months: the Enterics for Global Health (EFGH) - Shigella Burden Study

Actual Study Start Date :

Aug 25, 2022

Anticipated Primary Completion Date :

Dec 25, 2024

Anticipated Study Completion Date :

May 31, 2025

Arms and Interventions

Arm	Intervention/Treatment
Children with Shigella Diarrhea Children with Shigella identified by culture or quantitative PCR
Children without Shigella Diarrhea Children without Shigella identified by culture or quantitative PCR

Outcome Measures

Primary Outcome Measures

Shigella incidence [At enrollment in the study (cross-sectional)]
The primary outcome measure is Shigella incidence, defined as incident diarrhea among children enrolled at health clinics attributable to Shigella by microbiological methods (culture or qPCR) divided by the estimated population living in the catchment area. Incidence will be reported as crude incidence as well as adjusted for healthcare seeking and the percentage of children who were enrolled.

Secondary Outcome Measures

Antimicrobial susceptibility [At enrollment in the study (cross-sectional)]
Antimicrobial susceptibility will be computed separately for Ampicillin, Azithromycin, Ceftriaxone, Ciprofloxacin, Nalidixic Acid, Pivmecillinam, and Trimethoprim-Sulfamethoxazole and defined as intermediate or resistant according to the most recent Clinical and Laboratory Standards Institute (CLSI) interpretive standards at the time of data analysis.
Cost per episode treated [3 months]
Cost per episode treated will be calculated using the direct and indirect financial costs and total economic costs of illness per outpatient and inpatient episode of Shigella-associated diarrhea from the household and, separately, payer perspectives.
Death [3 months]
Death: all cause mortality during follow-up among enrolled children.
Hospitalization [3 months]
Hospitalization will be defined as an overnight stay (child was on the ward from at least 12am to 6am) that occurs during follow-up among enrolled children
Persistent diarrhea (index episode) [3 months]
Persistent diarrhea will be defined as 14 or more days of diarrhea (starting from the date at which the diarrhea first started (as opposed to date at presentation to an EFGH facility) and concluding at the last day of diarrhea prior to the two consecutive diarrhea-free days concluding the episode.
Diarrhea/dysentery recurrence [3 months]
Diarrhea/dysentery recurrence will be defined as new diarrhea/dysentery episodes (>48 hours after a diarrhea-free period).
Change in linear growth [3 months]
Change in mean length/height-for-age z-score (∆LAZ/∆HAZ) from enrollment to 3 months. The 2006 World Health Organization (WHO) reference population will be used to calculate HAZ from the average of two repeated length/height (cm) measures per child per time point

Eligibility Criteria

Criteria

Ages Eligible for Study:

6 Months to 35 Months

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Child is 6-35 months of age
Primary caregiver and child plan to remain at their current residence for at least the next 4 months
Primary caregiver is able to provide informed consent (legal age or emancipated minor) and provides consent within a common language for which translations are available
Child presents to health facility with diarrhea (≥3 abnormally loose or watery stools in the previous 24 hours) with or without the presence of blood
Child resides within the pre-defined study area
Fewer than 4 hours have passed since the child presented to a health facility
Diarrhea episode is:

Acute (onset within 7 days of study enrollment) and
Represents a new episode (onset after at least 2 diarrhea-free days)

Caregiver is willing to have child participate in follow-up visits at week 4 and month 3
Willingness to have samples collected from the child (rectal swabs at enrollment)
Site enrollment cap has not been met
Child is not being referred to a non-EFGH facility at the time of screening

Exclusion Criteria:

Child is < 6-35 months of age
Child is > 6-35 months of age
Primary caregiver and child do not plan to remain at their current residence for at least the next 4 months
Primary caregiver is not able to provide informed consent (legal age or emancipated minor)
Primary caregiver does not provide consent within a common language for which translations are available
Child does not present to health facility with diarrhea (≥3 abnormally loose or watery stools in the previous 24 hours) with or without the presence of blood
Child does not reside within the pre-defined study area
4 or more hours have passed since the child presented to a health facility
Diarrhea episode is not Acute (onset within 7 days of study enrollment)
Diarrhea episode does not represent a new episode (onset after at least 2 diarrhea-free days)
Caregiver is unwilling to have child participate in follow-up visits at week 4 and month 3
Unwillingness to have samples collected from the child (rectal swabs at enrollment)
Site enrollment cap has been met
Child is being referred to a non-EFGH facility at the time of screening

Contacts and Locations

Locations

	Site	City	State	Country
1	Dhaka Medical College Hospital	Dhaka		Bangladesh
2	EFGH Field Clinic	Dhaka		Bangladesh
3	icddr,b Dhaka Hospital	Dhaka		Bangladesh
4	Mugda Medical College Hospital	Dhaka		Bangladesh
5	Sir Salimullah Medical College Hospital	Dhaka		Bangladesh
6	Basse Hospital	Basse Santa Su	Upper River Region	Gambia
7	Gambisara Health Centre (HC)	Basse Santa Su	Upper River Region	Gambia
8	Abidha Health Center	Siaya		Kenya
9	Akala Health Center	Siaya		Kenya
10	Bar Agulu Health Center	Siaya		Kenya
11	Dienya Health Centre	Siaya		Kenya
12	Lwak Mission Hospital	Siaya		Kenya
13	Ongielo Health Centre	Siaya		Kenya
14	Siaya County Referral Hospital	Siaya		Kenya
15	Ting Wangi Health Center	Siaya		Kenya
16	Wagai Health Center	Siaya		Kenya
17	Ndirande Health Centre	Blantyre		Malawi
18	Asacodjeneka Cscom	Bamako		Mali
19	Asacodjip Cscom	Bamako		Mali
20	Banconi CSCOM (ASACOBA)	Bamako		Mali
21	CSREF Commune 1	Bamako		Mali
22	Abbasi Shaheed Hospital	Karachi		Pakistan
23	Ali Akbar Shah Center	Karachi		Pakistan
24	Bhains colony AKU site	Karachi		Pakistan
25	Khidmat e Alam Medical Centre	Karachi		Pakistan
26	Sindh Government Hospital, Ibrahim Hyderi	Karachi		Pakistan
27	Sindh Government Hospital, Korangi	Karachi		Pakistan
28	America Health Post	Iquitos	Maynas	Peru
29	Hospital de Apoloyo	Iquitos	Maynas	Peru
30	Modelo Health Post	Iquitos	Maynas	Peru
31	Progreso Health Post	Iquitos	Maynas	Peru
32	San Juan Health Post	Iquitos	Maynas	Peru
33	Santo Tomas Health Post	Iquitos	Maynas	Peru